Format

Send to

Choose Destination
Cancer Cell. 2011 Apr 12;19(4):437-40. doi: 10.1016/j.ccr.2011.03.020.

Resisting targeted therapy: fifty ways to leave your EGFR.

Author information

1
Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, UK. Paul.workman@icr.ac.uk

Abstract

Despite the promise of the new generation of molecularly targeted drugs, intrinsic and acquired resistance is proving to be as problematic as with cytotoxic drugs. Two recent papers have identified novel ways by which non-small cell lung cancers can exhibit resistance to EGFR inhibitors and suggest new therapeutic workarounds.

PMID:
21481786
DOI:
10.1016/j.ccr.2011.03.020
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center